FDA Clocks VYLOY's Review for Extra Patent Years
Published Date: 4/3/2026
Notice
Summary
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
VYLOY patent-extension eligibility set
The FDA determined the regulatory review period for the biologic VYLOY is 2,471 days: a 1,945-day testing phase and a 526-day approval phase. Key dates are: IND effective January 14, 2018; BLA submitted May 12, 2023; BLA approved October 18, 2024. This determination establishes the maximum potential patent-extension period and the applicant has applied to the USPTO seeking extensions of 66; 671; 990; 1,028; 1,319; 1,340; 1,406; 1,410; or 1,499 days for the listed patents.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in